文献速递毛发、甲与色素性疾病

Ivarmacitinib治疗成人重度斑秃:3期试验结果

Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial.
PubMed 文献 · J Am Acad Dermatol · 2025-09-19

这项随机双盲3期试验纳入330例重度斑秃成人患者,按1:1:1分配接受Ivarmacitinib 4 mg、8 mg或安慰剂每日一次治疗24周。第24周时,SALT≤20达标率分别为34.9%、40.6%和9.0%,与安慰剂的绝对差异分别为25.6%(95%CI 15.4-35.7)和31.6%(95%CI 21.5-41.8),均P<.0001。多数不良事件为轻中度,未报告死亡、主要心血管事件或血栓栓塞事件。

要点

  • Ivarmacitinib 4 mg和8 mg每日一次治疗24周可促进重度斑秃患者毛发再生。
  • 第24周SALT≤20达标率:4 mg组34.9%、8 mg组40.6%、安慰剂组9.0%。
  • 安全性可接受,多数不良事件为轻中度,未报告死亡或血栓栓塞事件。

核心结论

  • 每日一次Ivarmacitinib 4 mg或8 mg在重度斑秃患者中带来有意义的毛发再生,安全性可接受。

研究设计与样本

  • 随机、双盲、3期试验,330例重度斑秃成人患者按1:1:1分配接受Ivarmacitinib 4 mg、8 mg或安慰剂每日一次治疗24周。
  • 安慰剂组患者在28周延长期内重新随机分配接受Ivarmacitinib治疗。

主要发现

  • 第24周SALT≤20达标率:4 mg组34.9%、8 mg组40.6%、安慰剂组9.0%。
  • 与安慰剂的绝对差异:4 mg组25.6%(95%CI 15.4-35.7),8 mg组31.6%(95%CI 21.5-41.8),均P<.0001。
  • 治疗中出现的不良事件发生率分别为77.1%、84.7%和75.5%,大多数为轻中度。
  • 未报告死亡、主要心血管事件或血栓栓塞事件。

关键数值与推荐

  • 主要终点为第24周达到SALT评分≤20的患者比例。
  • 重度斑秃定义为头皮脱发≥50%,包括全秃/普秃。

临床怎么用

  • Ivarmacitinib 4 mg或8 mg每日一次可作为重度斑秃成人患者的治疗选择。
  • 治疗期间需关注不良事件,多数为轻中度。

局限性

  • 未使用阳性对照药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, demonstrated efficacy in a phase 2 trial for moderate-to-severe alopecia areata (AA). OBJECTIVE: To evaluate the efficacy and safety of ivarmacitinib in adults with severe AA (≥50% scalp hair loss, including alopecia totalis/universalis). METHODS: In this randomized, double-blind, phase 3 trial, 330 patients were assigned (1:1:1) to ivarmacitinib 4 mg, 8 mg, or placebo once daily for 24 weeks. Placebo recipients were re-randomized to ivarmacitinib for a 28-week extension. The primary endpoint was the proportion achieving a Severity of Alopecia Tool (SALT) score ≤20 at week 24. RESULTS: At week 24, SALT ≤20 was achieved by 34.9% (4 mg), 40.6% (8 mg), and 9.0% (placebo). Absolute differences versus placebo were 25.6% (95% CI: 15.4-35.7) for 4 mg and 31.6% (21.5-41.8) for 8 mg (both P < .0001). Treatment-emergent adverse events occurred in 77.1%, 84.7%, and 75.5% of patients, respectively; most were mild or moderate. No deaths, major cardiovascular events, or thromboembolic events were reported. LIMITATION: No active comparator was used. CONCLUSION: Once-daily ivarmacitinib 4 mg or 8 mg resulted in meaningful hair regrowth and demonstrated an acceptable safety profile in patients with severe AA.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Zhou C, Yang C, Fan W, et al. Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial. J Am Acad Dermatol. 2025. PMID: 40976531. doi:10.1016/j.jaad.2025.09.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。